473 related articles for article (PubMed ID: 26044126)
61. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
[TBL] [Abstract][Full Text] [Related]
62. Sex-, age-, and organ-dependent improvement of bile acid hydrophobicity by ursodeoxycholic acid treatment: A study using a mouse model with human-like bile acid composition.
Ueda H; Honda A; Miyazaki T; Morishita Y; Hirayama T; Iwamoto J; Nakamoto N; Ikegami T
PLoS One; 2022; 17(7):e0271308. PubMed ID: 35819971
[TBL] [Abstract][Full Text] [Related]
63. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.
Roma MG; Toledo FD; Boaglio AC; Basiglio CL; Crocenzi FA; Sánchez Pozzi EJ
Clin Sci (Lond); 2011 Dec; 121(12):523-44. PubMed ID: 21854363
[TBL] [Abstract][Full Text] [Related]
64. Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver.
Benedetti A; Alvaro D; Bassotti C; Gigliozzi A; Ferretti G; La Rosa T; Di Sario A; Baiocchi L; Jezequel AM
Hepatology; 1997 Jul; 26(1):9-21. PubMed ID: 9214446
[TBL] [Abstract][Full Text] [Related]
65. Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats.
Purucker E; Marschall HU; Winograd R; Matern S
Biochim Biophys Acta; 2001 Apr; 1526(1):44-52. PubMed ID: 11287121
[TBL] [Abstract][Full Text] [Related]
66. Effects of selective zonal injury on bile acid-induced bile flow in the isolated rat liver.
Monte MJ; Badia MD; Palomero F; el-Mir MY; Alonso JR; Marin JJ
Am J Physiol; 1993 Jun; 264(6 Pt 1):G1103-11. PubMed ID: 8333538
[TBL] [Abstract][Full Text] [Related]
67. Antioxidant mechanism of hepatoprotection by ursodeoxycholic acid in experimental alcoholic steatohepatitis.
Lukivskaya O; Zavodnik L; Knas M; Buko V
Adv Med Sci; 2006; 51():54-9. PubMed ID: 17357278
[TBL] [Abstract][Full Text] [Related]
68. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway.
Hu J; Hong W; Yao KN; Zhu XH; Chen ZY; Ye L
World J Gastroenterol; 2019 Mar; 25(12):1492-1501. PubMed ID: 30948912
[TBL] [Abstract][Full Text] [Related]
69. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis.
Colombo C; Setchell KD; Podda M; Crosignani A; Roda A; Curcio L; Ronchi M; Giunta A
J Pediatr; 1990 Sep; 117(3):482-9. PubMed ID: 2391610
[TBL] [Abstract][Full Text] [Related]
70. Bile acid receptors in the biliary tree: TGR5 in physiology and disease.
Deutschmann K; Reich M; Klindt C; Dröge C; Spomer L; Häussinger D; Keitel V
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1319-1325. PubMed ID: 28844960
[TBL] [Abstract][Full Text] [Related]
71. Ursodeoxycholic acid and in vitro vasoactivity of hydrophobic bile acids.
Bomzon A; Ljubuncic P
Dig Dis Sci; 2001 Sep; 46(9):2017-24. PubMed ID: 11575458
[TBL] [Abstract][Full Text] [Related]
72. Effects of ursodeoxycholic acid and chenodeoxycholic acid on human hepatocytes in primary culture.
Hillaire S; Ballet F; Franco D; Setchell KD; Poupon R
Hepatology; 1995 Jul; 22(1):82-7. PubMed ID: 7601437
[TBL] [Abstract][Full Text] [Related]
73. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.
Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Gradilone SA; Huang B; Masyuk AI; Hogan MC; Torres VE; Larusso NF
Hepatology; 2013 Jul; 58(1):409-21. PubMed ID: 23172758
[TBL] [Abstract][Full Text] [Related]
74. Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat.
Masyuk TV; Huang BQ; Ward CJ; Masyuk AI; Yuan D; Splinter PL; Punyashthiti R; Ritman EL; Torres VE; Harris PC; LaRusso NF
Gastroenterology; 2003 Nov; 125(5):1303-10. PubMed ID: 14598246
[TBL] [Abstract][Full Text] [Related]
75. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
[TBL] [Abstract][Full Text] [Related]
76. The effects of ursodeoxycholic acid on serum and biliary noncholesterol sterols in patients with gallstones.
Miettinen TE; Tarpila S; Gylling H
Hepatology; 1997 Mar; 25(3):514-8. PubMed ID: 9049189
[TBL] [Abstract][Full Text] [Related]
77. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation.
Rodrigues CM; Fan G; Ma X; Kren BT; Steer CJ
J Clin Invest; 1998 Jun; 101(12):2790-9. PubMed ID: 9637713
[TBL] [Abstract][Full Text] [Related]
78. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells.
Arenas F; Hervias I; Uriz M; Joplin R; Prieto J; Medina JF
J Clin Invest; 2008 Feb; 118(2):695-709. PubMed ID: 18188457
[TBL] [Abstract][Full Text] [Related]
79. Effect of ursodeoxycholic acid administration on bile duct proliferation and cholestasis in bile duct ligated rat.
Frezza EE; Gerunda GE; Plebani M; Galligioni A; Giacomini A; Neri D; Faccioli AM; Tiribelli C
Dig Dis Sci; 1993 Jul; 38(7):1291-6. PubMed ID: 8325189
[TBL] [Abstract][Full Text] [Related]
80. Application of ursodeoxycholic acid (UDCA) in the therapy of liver and biliary duct diseases in children.
Lebensztejn DM
Med Sci Monit; 2000; 6(3):632-6. PubMed ID: 11208384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
